Allscripts Healthcare Solutions Inc. (NASDAQ:MDRX) was downgraded by equities researchers at Deutsche Bank AG from a “buy” rating to a “hold” rating in a report released on Thursday. They presently have a $11.00 target price on the stock, down from their previous target price of $14.00. Deutsche Bank AG’s target price would indicate a potential upside of 7.32% from the company’s previous close.

MDRX has been the topic of a number of other research reports. Morgan Stanley restated a “buy” rating on shares of Allscripts Healthcare Solutions in a research report on Thursday, August 25th. Zacks Investment Research downgraded shares of Allscripts Healthcare Solutions from a “hold” rating to a “sell” rating in a research report on Tuesday, October 25th. Canaccord Genuity restated a “buy” rating and issued a $19.00 price target on shares of Allscripts Healthcare Solutions in a research report on Sunday, September 11th. Argus upgraded shares of Allscripts Healthcare Solutions from a “hold” rating to a “buy” rating in a research report on Thursday, August 25th. Finally, Cowen and Company downgraded shares of Allscripts Healthcare Solutions from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $17.00 to $14.00 in a research report on Thursday, September 8th. Eleven analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $15.59.

Analyst Recommendations for Allscripts Healthcare Solutions (NASDAQ:MDRX)

Allscripts Healthcare Solutions (NASDAQ:MDRX) opened at 10.25 on Thursday. The company’s market cap is $1.90 billion. Allscripts Healthcare Solutions has a 52-week low of $9.80 and a 52-week high of $15.78. The company has a 50-day moving average of $12.32 and a 200-day moving average of $13.02.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last issued its quarterly earnings results on Thursday, November 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.15 by $0.01. The firm earned $392.40 million during the quarter, compared to analyst estimates of $414.92 million. Allscripts Healthcare Solutions had a positive return on equity of 5.79% and a negative net margin of 0.14%. The firm’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.13 EPS. On average, equities research analysts expect that Allscripts Healthcare Solutions will post $0.56 earnings per share for the current fiscal year.

In other Allscripts Healthcare Solutions news, SVP James Hewitt sold 17,500 shares of the company’s stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $13.00, for a total transaction of $227,500.00. Following the sale, the senior vice president now directly owns 158,104 shares of the company’s stock, valued at $2,055,352. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Paul Black sold 15,000 shares of the company’s stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $13.00, for a total transaction of $195,000.00. Following the sale, the chief executive officer now directly owns 1,177,009 shares in the company, valued at $15,301,117. The disclosure for this sale can be found here. Corporate insiders own 0.75% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in MDRX. Boston Advisors LLC increased its stake in Allscripts Healthcare Solutions by 0.5% in the second quarter. Boston Advisors LLC now owns 50,367 shares of the company’s stock valued at $640,000 after buying an additional 250 shares during the period. Nicolet Bankshares Inc. increased its stake in Allscripts Healthcare Solutions by 2.3% in the third quarter. Nicolet Bankshares Inc. now owns 13,075 shares of the company’s stock valued at $172,000 after buying an additional 300 shares during the period. Aspen Investment Management Inc increased its stake in Allscripts Healthcare Solutions by 1.8% in the third quarter. Aspen Investment Management Inc now owns 23,135 shares of the company’s stock valued at $305,000 after buying an additional 400 shares during the period. Capstone Asset Management Co. increased its stake in Allscripts Healthcare Solutions by 3.1% in the second quarter. Capstone Asset Management Co. now owns 16,387 shares of the company’s stock valued at $208,000 after buying an additional 500 shares during the period. Finally, IBM Retirement Fund increased its stake in Allscripts Healthcare Solutions by 3.9% in the second quarter. IBM Retirement Fund now owns 18,847 shares of the company’s stock valued at $239,000 after buying an additional 708 shares during the period.

About Allscripts Healthcare Solutions

Allscripts Healthcare Solutions, Inc delivers information technology (IT) and services to help healthcare organizations in clinical, financial and operational results. The Company operates through two segments: Clinical and Financial Solutions, and Population Health. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions, which primarily include electronic health record (EHR)-related software, financial and practice management software, related installation, support and maintenance, outsourcing, hosting, revenue cycle management, training and electronic claims administration services.

5 Day Chart for NASDAQ:MDRX

Receive News & Stock Ratings for Allscripts Healthcare Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions Inc. and related stocks with our FREE daily email newsletter.